Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors

Romidepsin is a histone deacetylase inhibitor (HDI), approved by the US FDA for the treatment of cutaneous T-cell lymphoma (CTCL). Although various mechanisms have been proposed for the activity of HDls, including induction of genes controlling cell cycle, acetylation of cytoplasmic proteins and dir...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Expert Rev Anticancer Ther
Главные авторы: Grant, Cliona, Rahman, Fahd, Piekarz, Richard, Peer, Cody, Frye, Robin, Robey, Robert W, Gardner, Erin R, Figg, William D, Bates, Susan E
Формат: Artigo
Язык:Inglês
Опубликовано: 2010
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6361116/
https://ncbi.nlm.nih.gov/pubmed/20645688
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/era.10.88
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы